Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics

Accumulating evidence showed that brain-derived neurotrophic factor (BDNF) may be involved in the pathophysiology of schizophrenia. Decreased BDNF levels have been found in the serum of schizophrenic patients with mixed results. In the present study, we assessed serum BDNF levels in a large group of 364 schizophrenic patients (157 on clozapine, 89 on risperidone and 118 on typical antipsychotics), compared to 323 healthy control subjects matched for age and gender. The schizophrenia symptomatology was assessed by the Positive and Negative Syndrome Scale (PANSS), and serum BDNF levels were measured by sandwich ELISA. The results showed that BDNF levels were significantly lower in chronic patients with schizophrenia than in healthy control subjects (9.9+/-2.0 ng/ml vs.11.9+/-2.3 ng/ml, p<0.0001). Lower BDNF levels were observed in patients treated with risperidone (9.3+/-2.3 ng/ml) compared to those with clozapine (10.2+/-2.0 ng/ml, p<0.001) and typical antipsychotics (10.0+/-2.1 ng/ml, p<0.01). Furthermore, a stepwise multiple regression analysis identified types of antipsychotic drugs (beta=-0.37, t=-3.15, p=0.001) and BDNF levels (beta=-0.26, t=-2.51, p=0.014) as the influencing factor for the positive symptom subscore of PANSS. In addition, there was a sex difference in BDNF levels in patients with schizophrenia (9.7+/-1.9 ng/ml for males vs.10.4+/-2.1 ng/ml for female, p<0.005), but not in normal controls. Our findings indicated decreased BDNF serum levels in chronic patients with schizophrenia, which may be related to clinical phenotypes, including gender, antipsychotic treatment and the severity of psychotic symptoms.

[1]  Alexander L. Miller,et al.  First-Episode Psychosis: A Window of Opportunity for Best Practices , 2007, CNS Spectrums.

[2]  Y. Loh,et al.  A bi-directional carboxypeptidase E-driven transport mechanism controls BDNF vesicle homeostasis in hippocampal neurons , 2008, Molecular and Cellular Neuroscience.

[3]  F. Taneli,et al.  Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  K. Hashimoto,et al.  Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls , 2003, Neuroscience Letters.

[5]  F. Angelucci,et al.  Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions. , 2000, The international journal of neuropsychopharmacology.

[6]  H. Danker-Hopfe,et al.  Brain-derived neurotrophic factor serum concentrations are increased in drug-naïve schizophrenic patients with chronic cannabis abuse and multiple substance abuse , 2004, Neuroscience Letters.

[7]  D. Souza,et al.  Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. , 2007, Journal of psychiatric research.

[8]  J. Thome,et al.  Neurotrophic factors and the pathophysiology of schizophrenic psychoses , 2004, European Psychiatry.

[9]  Chien-Te Lee,et al.  Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. , 2006, Journal of psychiatric research.

[10]  F. Mosquera,et al.  Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients , 2006, Schizophrenia Research.

[11]  Abraham Weizman,et al.  The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia , 2005, European Neuropsychopharmacology.

[12]  Kenji Hashimoto,et al.  Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: The possibility to explain ethnic mental traits , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[13]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[14]  M. Berk,et al.  Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder , 2007, Neuroscience Letters.

[15]  S. Radka,et al.  Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay , 1996, Brain Research.

[16]  Zin Z. Khaing,et al.  BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs , 2001, The European journal of neuroscience.

[17]  M. Schwald,et al.  Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets , 2002, Neuroscience Letters.

[18]  H. Nawa,et al.  Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients , 2002, Psychiatry Research.

[19]  H. Qing,et al.  Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus , 2002, Neuroscience Letters.

[20]  K. Nylen,et al.  Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration , 2002, Brain Research.

[21]  T. Kosten,et al.  BDNF Levels and Genotype are Associated with Antipsychotic-Induced Weight Gain in Patients with Chronic Schizophrenia , 2008, Neuropsychopharmacology.

[22]  J. Virchow,et al.  The impact of age, weight and gender on BDNF levels in human platelets and plasma , 2004, Neurobiology of Aging.

[23]  H Nawa,et al.  Cytokine and growth factor involvement in schizophrenia—support for the developmental model , 2000, Molecular Psychiatry.

[24]  J. Kleinman,et al.  Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia , 2003, Molecular Psychiatry.

[25]  A. Teixeira,et al.  Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia , 2008, Neuroscience Letters.

[26]  A. Genazzani,et al.  Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. , 2007, Human reproduction.

[27]  R. Yoshimura,et al.  Increase of plasma brain-derived neurotrophic factor levels in two psychotic depressed patients responding to lithium addition to paroxetine treatment , 2007, Neuropsychiatric disease and treatment.

[28]  A. Terry,et al.  Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus , 2006, Schizophrenia Research.

[29]  X. Zhang,et al.  Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics , 2005, Neuroscience Letters.

[30]  Yan Shen,et al.  Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. , 2007, Journal of psychiatric research.

[31]  D. Keegan,et al.  Expression of brain‐derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs , 2003, Journal of neuroscience research.

[32]  N. Yahata,et al.  Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia , 2008, Schizophrenia Research.

[33]  William A Banks,et al.  Transport of brain-derived neurotrophic factor across the blood–brain barrier , 1998, Neuropharmacology.

[34]  A. Kastania,et al.  Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.